Home Archives for ovarian cancer

Other Cancers Seen in Families with RAD51D Mutations

Posted on August 9, 2011 Written by Leave a Comment

Two days ago we discussed a recent study by Dr. Nazneen Rahman and colleagues which clearly demonstrated that inherited mutations in a gene called RAD51D result in a substantial elevation in risk for ovarian cancer. This elevation in risk was seen in some families in which other cancer types were seen in the family tree. So, does this mean that the other cancer types in these families are also due to the RAD51D mutations?

Filed Under: Breast Cancer, Cancer, Cancer Genetics, Colon Cancer, Family History, Lung Cancer, Lymphoma, Non-Hodgkin Lymphoma, Pancreatic Cancer, Prostate Cancer, RAD51D Tagged: , , , , , , , , , , ,

RAD51D – A New Hereditary Ovarian Cancer Gene With Important Implications

Posted on August 7, 2011 Written by Leave a Comment

If you have a compelling family history of ovarian cancer that is not explained by a mutation in the BRCA1 or BRCA2 gene, it is possible that a mutation in the RAD51D gene could be the explanation.

Filed Under: BRCA1, BRCA2, Cancer Genetics, Cancer Prevention, Cancer Screening, Family History, Hereditary Breast and Ovarian Cancer, Ovarian Cancer, PARP Inhibitors, RAD51D, Risk-Reducing Salpingo-Oophorectomy Tagged: , , , , , , , , ,

Woman Files Complaint Claiming She Was Fired Over Positive BRCA2 Test for Hereditary Breast and Ovarian Cancer

Posted on April 28, 2010 Written by Leave a Comment

In one of the first complaints filed related to the Genetic Insurance Nondiscrimination Act, a Connecticut woman has filed complaints with the U.S. Equal Opportunity Commission and the Connecticut Commission on Human Rights and Opportunities. According to the Boston Herald, Pamela Fink, 39, of Fairfield, Connecticut, alleges that her employer, MXenergy fired her after she disclosed to them that she had a mutation in the BRCA2 gene (which confers hereditary breast and ovarian cancer susceptibility).

Filed Under: BRCA1, BRCA2, Breast Cancer, Cancer Genetics, Cancer Prevention, ELSI (Ethical, Legal, and Social Issues), GINA, Hereditary Breast and Ovarian Cancer, Ovarian Cancer, Prophylactic Mastectomy Tagged: , , , , , , , , , ,

Myriad Breast Cancer Gene Patents and the Courts: Upcoming Genetic Alliance Webinar

Posted on April 26, 2010 Written by Leave a Comment

We’ve mentioned the court case involving the Myriad breast cancer gene patents several times here at Cancer and Your Genes. Recently, we’ve discussed the rather surprising summary judgment decision invalidating some of Myriad Genetics’ patents on the BRCA1 and BRCA2 genes. This is just the opening salvo in a fight that may make it all the way to the Supreme Court.

Filed Under: BRCA1, BRCA2, Breast Cancer, Cancer Genetics, ELSI (Ethical, Legal, and Social Issues), Hereditary Breast and Ovarian Cancer Tagged: , , , , , , , , , , ,

RAD51C: A New Hereditary Breast and Ovarian Cancer Gene

Posted on April 20, 2010 Written by 2 Comments

If you have a compelling family history of breast and ovarian cancer that is not explained by a mutation in the BRCA1 or BRCA2 gene, it is possible that the RAD51C gene could be the explanation. An international research team demonstrated that mutations in RAD51C can lead to hereditary breast and ovarian cancer risk in a paper published online in Nature Genetics yesterday.

Filed Under: BRCA1, BRCA2, Breast Cancer, BRIP1, Cancer Genetics, Common Disease, Rare Gene/Rare Allele Hypothesis, Family History, Fanconi Anemia, Hereditary Breast and Ovarian Cancer, Ovarian Cancer, PALB2, RAD51C Tagged: , , , , , , , , , , , , , ,

Breast Cancer Gene Patenting Lawsuit Pitting ACLU, ACMG and Others Against Myriad Genetics and University of Utah Research Foundation Will Continue

Posted on November 3, 2009 Written by Leave a Comment

A judge refused to throw out the lawsuit which could plausibly have broad implications for gene patenting…but seems more likely to me to be posturing to encourage a political/legislative solution. Ars Technica has excellent coverage here.

Filed Under: BRCA1, BRCA2, Breast Cancer, Cancer Genetics, ELSI (Ethical, Legal, and Social Issues), Hereditary Breast and Ovarian Cancer, Ovarian Cancer Tagged: , , , , , ,

Mechanism of Cisplatin-Resistance in BRCA2-Related Ovarian Cancers

Posted on February 10, 2008 Written by 2 Comments

Two papers published online today in the journal Nature (abstracts available here and here) show us why this is the case at least in a subset of cases in individuals with BRCA2 mutations.

Filed Under: BRCA2, Breast Cancer, Cisplatin, Hereditary Breast and Ovarian Cancer, Molecularly Targeted Therapy, Ovarian Cancer, PARP Inhibitors Tagged: , , , , , , , , , , ,